Bio-Rad Laboratories, Inc.

NYSE:BIO

Medical - Devices

Healthcare
$370.17 -0.23%

-$0.65 today

Market cap
$9.95B
Beta
1.08
P/E (TTM)
45.4
EPS (TTM)
$6.26
52W Low $228.40High $343.12

Volume 0.46M

Average 0.38M

BIO Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Bio-Rad Laboratories, Inc.NYSE: BIO

Weighted Avg Shares (Diluted) · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares (diluted) declines year over year

Q2 FY2026 weighted avg shares (diluted) of 26.81M shares fell 1.5% year over year, ahead of the -3.1% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it fell 0.5% from the prior quarter. Over 3 fiscal years it compounded at -2.9% a year.

Context

  • Weighted avg shares (diluted) increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -1.5% holds above the trailing-twelve-month pace of -3.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
26.81M-0.5% QoQ
Last fiscal yearDec 2025
27.28M-3.3% YoY
LTMJun 2026
26.93M-3.1% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1.5%——
1 year-3.3%——
3-year CAGR-2.9%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
27.28M USD
Year-over-year change
-3.3%
4-year CAGR
-2.5%

Weighted Avg Shares (Diluted) vs competitors

How BIO compares with its peers on the latest reported figures

  • BIO's LTM Jun 2026 weighted avg shares (diluted) of 26.93M shares is the lowest of the 11 companies compared; the peer median is 154.76M shares.
  • Its year-over-year change of -3.1% is the 10th highest of 11, against a peer median of -0.2%.
  • Over three fiscal years its annual growth of -2.9% compares with a peer median of -0.8%.
BIO Competitors Peer median
Weighted Avg Shares (Diluted) for BIO and competitors
Company Period LTM YoY 3-year CAGR
DHRDanaher CorporationLTM Sep 2026709.15M -1.9%-1.2%
LABStandard BioTools Inc.LTM Mar 2026384.09M +2.7%+69.5%
TMOThermo Fisher Scientific Inc.LTM Sep 2026373M -1.7%-1.5%
PACBPacific Biosciences of California, Inc.LTM Mar 2026302.18M +5.2%+10.1%
TECHBio-Techne CorporationLTM Sep 2026157.22M -0.4%-1.0%
BRKRBruker CorporationLTM Jun 2026152.3M +0.3%+0.5%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026146.04M +2.7%+3.3%
RVTYRevvity, Inc.LTM Jul 2026113.64M -5.8%-3.6%
RGENRepligen CorporationLTM Jun 202656.59M +0.1%-0.5%
AZTAAzenta, Inc.LTM Sep 202645.19M -1.3%-12.0%
BIOBio-Rad Laboratories, Inc.LTM Jun 202626.93M -3.1%-2.9%
Peer median (excluding BIO) 154.76M-0.2%-0.8%

Competitors are the stored peer set for BIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.92B2.8B2.67B2.57B2.58B
Cost of Revenue1.28B1.23B1.24B1.19B1.24B
Gross Profit1.64B1.57B1.43B1.38B1.34B
Gross Margin56.1%55.9%53.4%53.7%52.0%
Research & Development260.64M256.89M247.43M295.9M256.9M
Selling, General & Admin877.12M827.83M841.7M814M819.9M
Operating Expenses1.14B1.08B1.09B1.11B1.08B
Depreciation & Amortization137.6M137.3M145.9M151.6M165.4M
EBITDA5.59B(4.53B)(654.8M)(2.14B)1.21B
EBITDA Margin191.2%-161.6%-24.5%-83.5%46.8%
Operating Income500.34M482.62M337.8M269M270.5M
Operating Margin17.1%17.2%12.6%10.5%10.5%
Interest Income18.9M58M100.9M82M95.5M
Interest Expense1.55M38.11M49.44M48.9M49M
Other Income / Expenses4.95B(5.19B)(1.19B)(2.61B)725M
Income Before Tax5.45B(4.7B)(850.1M)(2.34B)995.5M
Pre-Tax Margin186.4%-167.9%-31.8%-91.3%38.5%
Income Tax Expense1.19B(1.08B)(212.78M)(498.3M)235.6M
Net Income4.25B(3.63B)(637.32M)(1.84B)759.9M
Net Margin145.6%-129.5%-23.9%-71.9%29.4%
EPS (Basic)142.61(121.79)(21.82)(65.36)27.87
EPS (Diluted)140.83(121.79)(21.82)(65.36)27.87
Weighted Avg Shares29.83M29.79M29.21M28.21M27.26M
Weighted Avg Shares (Diluted)30.21M29.79M29.21M28.21M27.28M

Bio-Rad Laboratories, Inc.

NYSE:BIO

Intrinsic Alpha fair value

Locked

Current Price

$370.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.